The U.S. Centers for Disease Control and Prevention (CDC) has announced a significant, controversial revision to American public-health policy, drastically scaling back its universal childhood vaccine recommendations. Announced on 5 January 2026, the move reduces the number of routinely recommended vaccines for all children from approximately 17 to 11, immediately igniting a widespread debate among health professionals, parents, and policymakers.

‍

Under the revised guidance from the U.S. Department of Health and Human Services (HHS), several vaccines previously recommended for all children are no longer broadly advised for universal uptake. These now-optional vaccines include jabs against Influenza (flu), COVID-19, Rotavirus, Respiratory Syncytial Virus (RSV), Hepatitis A and Hepatitis B, and some meningococcal diseases. Instead, these vaccinations are now recommended only for children at high risk or are administered under a shared "clinical decision-making" model between doctors and parents. This model means a vaccine is given only after a discussion to weigh individual risks and preferences, rather than as a blanket recommendation for the entire population. The 11 remaining vaccines that Washington continues to recommend for all children are long-established immunisations, including those for Measles, mumps, rubella (MMR), Polio, Diphtheria, tetanus, and whooping cough, Haemophilus influenzae type b (Hib), Pneumococcal disease, Chickenpox, and Human papillomavirus (HPV) (though HPV dosing has been adjusted).

‍

Officials state the overhaul is intended to harmonise U.S. policy with some peer nations and to enhance public trust by offering more "transparent and flexible" guidance. The CDC and HHS confirm that all previously recommended vaccines remain available and that insurance coverage (including private plans, Medicaid, CHIP, and the Vaccines for Children programme) will continue to cover all immunisations on the updated schedule without cost-sharing.

‍

However, the change has drawn fierce opposition from public-health experts, including the American Academy of Pediatrics (AAP) and infectious disease specialists. Critics warn the shift could reduce vaccine uptake, particularly for diseases like flu and rotavirus, which historically cause significant paediatric hospitalisation. Many experts also fear the changes could undermine decades of progress, pointing to successes like the universal hepatitis B immunisation, which led to a drop of over 99% in infections among vaccinated cohorts. A major alarm is that the Advisory Committee on Immunization Practices (ACIP)—the usual scientific panel—was largely bypassed in the decision-making process, raising serious concerns about the evidence base and accountability of the decision.

‍

In response, several states, including California and Illinois, have declared they will retain comprehensive, evidence-based vaccine recommendations despite the federal changes, citing concerns about potential preventable outbreaks. Internationally, nations with national vaccination programmes, such as the UK, are closely monitoring the U.S. policy shift. British health leaders, guided by the Joint Committee on Vaccination and Immunisation (JCVI), emphasise the importance of robust, evidence-driven schedules tailored to national epidemiology and disease burden to maintain high coverage. The CDC’s decision is one of the most significant revisions to a national immunisation schedule in modern history, and its effects on disease incidence, vaccine confidence, and public health leadership are expected to unfold over the coming years, continuing the debate on balancing parental choice with population-level protection.

‍